Premature terminal differentiation protects from deregulated lymphocyte activation by itk-syk

Journal of Immunology

Volumn 192, Issue 3, 2014, Pages 1024-1033

  Bach, Martina P ^a,b   Hug, Eva ^b   Werner, Markus ^a,b   Holch, Julian ^c   Sprissler, Clara ^d   Pechloff, Konstanze ^c,e   Zirlik, Katja ^d   Zeiser, Robert ^d   Dierks, Christine ^d   Ruland, Jürgen ^c,e   Jumaa, Hassan ^a,b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; GAMMA INTERFERON; HERMES ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 INDUCIBLE KINASE; INTERLEUKIN 4; INTERLEUKIN 6; L SELECTIN; PROTEIN KINASE; PROTEIN KINASE SYK; STAT3 PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CELL EXPANSION; CELL MATURATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; INFLAMMATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; MOUSE; NONHUMAN; ONCOGENE ITK SYK; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; T CELL LYMPHOMA;

AGE FACTORS; ANIMALS; B-LYMPHOCYTE SUBSETS; CELLS, CULTURED; CHIMERA; CYTOKINES; DNA, COMPLEMENTARY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPERGAMMAGLOBULINEMIA; INFLAMMATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOCYTE ACTIVATION; LYMPHOPOIESIS; LYMPHOPROLIFERATIVE DISORDERS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; ONCOGENE PROTEINS, FUSION; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-TYROSINE KINASES; RECOMBINANT FUSION PROTEINS; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTE SUBSETS; THYMUS GLAND; TRANSCRIPTION FACTORS; TRANSDUCTION, GENETIC; TRANSLOCATION, GENETIC;

EID: 84893361712     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300420     Document Type: Article

References (55)

1. Sada, K., T. Takano, S. Yanagi, and H. Yamamura. 2001. Structure and function of Syk protein-tyrosine kinase. J. Biochem. 130: 177-186.
2. Turner, M., P. J. Mee, P. S. Costello, O. Williams, A. A. Price, L. P. Duddy, M. T. Furlong, R. L. Geahlen, and V. L. Tybulewicz. 1995. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature 378: 298-302.
3. Cheng, A. M., B. Rowley, W. Pao, A. Hayday, J. B. Bolen, and T. Pawson. 1995. Syk tyrosine kinase required for mouse viability and B-cell development. Nature 378: 303-306.
4. Mócsai, A., J. Ruland, and V. L. Tybulewicz. 2010. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat. Rev. Immunol. 10: 387-402.
5. Chan, A. C., N. S. van Oers, A. Tran, L. Turka, C. L. Law, J. C. Ryan, E. A. Clark, and A. Weiss. 1994. Differential expression of ZAP-70 and Syk protein tyrosine kinases, and the role of this family of protein tyrosine kinases in TCR signaling. J. Immunol. 152: 4758-4766.
6. Palacios, E. H., and A. Weiss. 2007. Distinct roles for Syk and ZAP-70 during early thymocyte development. J. Exp. Med. 204: 1703-1715.
7. Buchner, M., S. Fuchs, G. Prinz, D. Pfeifer, K. Bartholomé, M. Burger, N. Chevalier, L. Vallat, J. Timmer, J. G. Gribben, et al. 2009. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res. 69: 5424-5432.
8. Chen, L., S. Monti, P. Juszczynski, J. Daley, W. Chen, T. E. Witzig, T. M. Habermann, J. L. Kutok, and M. A. Shipp. 2008. SYK-dependent tonic Bcell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 111: 2230-2237.
9. Feldman, A. L., D. X. Sun, M. E. Law, A. J. Novak, A. D. Attygalle, E. C. Thorland, S. R. Fink, J. A. Vrana, B. L. Caron, W. G. Morice, et al. 2008. Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas. Leukemia 22: 1139-1143.
10. Kuno, Y., A. Abe, N. Emi, M. Iida, T. Yokozawa, M. Towatari, M. Tanimoto, and H. Saito. 2001. Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12). Blood 97: 1050-1055.
11. Kanie, T., A. Abe, T. Matsuda, Y. Kuno, M. Towatari, T. Yamamoto, H. Saito, N. Emi, and T. Naoe. 2004. TEL-Syk fusion constitutively activates PI3-K/Akt, MAPK and JAK2-independent STAT5 signal pathways. Leukemia 18: 548-555.
12. Wossning, T., S. Herzog, F. Kohler, S. Meixlsperger, Y. Kulathu, G. Mittler, A. Abe, U. Fuchs, A. Borkhardt, and H. Jumaa. 2006. Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells. J. Exp. Med. 203: 2829-2840.
13. Streubel, B., U. Vinatzer, M. Willheim, M. Raderer, and A. Chott. 2006. Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia 20: 313-318.
14. Liao, X. C., and D. R. Littman. 1995. Altered T cell receptor signaling and disrupted T cell development in mice lacking Itk. Immunity 3: 757-769.
15. Berg, L. J., L. D. Finkelstein, J. A. Lucas, and P. L. Schwartzberg. 2005. Tec family kinases in T lymphocyte development and function. Annu. Rev. Immunol. 23: 549-600.
16. Dierks, C., F. Adrian, P. Fisch, H. Ma, H. Maurer, D. Herchenbach, C. U. Forster, C. Sprissler, G. Liu, S. Rottmann, et al. 2010. The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease. Cancer Res. 70: 6193-6204.
17. Pechloff, K., J. Holch, U. Ferch, M. Schweneker, K. Brunner, M. Kremer, T. Sparwasser, L. Quintanilla-Martinez, U. Zimber-Strobl, B. Streubel, et al. 2010. The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma. J. Exp. Med. 207: 1031-1044.
18. Homig-Holzel, C., C. Hojer, J. Rastelli, S. Casola, L. J. Strobl, W. Muller, L. Quintanilla-Martinez, A. Gewies, J. Ruland, K. Rajewsky, and U. Zimber-Strobl. 2008. Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-kappaB pathway and promotes lymphomagenesis. J. Exp. Med. 205: 1317-1329.
19. Soriano, P. 1999. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat. Genet. 21: 70-71.
20. Lee, P. P., D. R. Fitzpatrick, C. Beard, H. K. Jessup, S. Lehar, K. W. Makar, M. Pérez-Melgosa, M. T. Sweetser, M. S. Schlissel, S. Nguyen, et al. 2001. A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity 15: 763-774.
21. Orban, P. C., D. Chui, and J. D. Marth. 1992. Tissue-And site-specific DNA recombination in transgenic mice. Proc. Natl. Acad. Sci. USA 89: 6861-6865.
22. Adachi, T., W. W. Schamel, K. M. Kim, T. Watanabe, B. Becker, P. J. Nielsen, and M. Reth. 1996. The specificity of association of the IgD molecule with the accessory proteins BAP31/BAP29 lies in the IgD transmembrane sequence. EMBO J. 15: 1534-1541.
23. Meixlsperger, S., F. Kohler, T. Wossning, M. Reppel, M. Muschen, and H. Jumaa. 2007. Conventional light chains inhibit the autonomous signaling capacity of the B cell receptor. Immunity 26: 323-333.
24. Aifantis, I., J. Buer, H. von Boehmer, and O. Azogui. 1997. Essential role of the pre-T cell receptor in allelic exclusion of the T cell receptor beta locus. Immunity 7: 601-607.
25. Gartner, F., F. W. Alt, R. Monroe, M. Chu, B. P. Sleckman, L. Davidson, and W. Swat. 1999. Immature thymocytes employ distinct signaling pathways for allelic exclusion versus differentiation and expansion. Immunity 10: 537-546.
26. Kneba, M., I. Bolz, B. Linke, and W. Hiddemann. 1995. Analysis of rearranged T-cell receptor beta-chain genes by polymerase chain reaction (PCR) DNA sequencing and automated high resolution PCR fragment analysis. Blood 86: 3930-3937.
27. van Dongen, J. J., A. W. Langerak, M. Bruggemann, P. A. Evans, M. Hummel, F. L. Lavender, E. Delabesse, F. Davi, E. Schuuring, R. García-Sanz, et al. 2003. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17: 2257-2317.
28. Dailey, M. O. 1998. Expression of T lymphocyte adhesion molecules: regulation during antigen-induced T cell activation and differentiation. Crit. Rev. Immunol. 18: 153-184.
29. Zhu, J., and W. E. Paul. 2008. CD4 T cells: fates, functions, and faults. Blood 112: 1557-1569.
30. Paul, W. E., and R. A. Seder. 1994. Lymphocyte responses and cytokines. Cell 76: 241-251.
31. Kozak, M. 1991. Structural features in eukaryotic mRNAs that modulate the initiation of translation. J. Biol. Chem. 266: 19867-19870.
32. Sprent, J., and H. Kishimoto. 2002. The thymus and negative selection. Immunol. Rev. 185: 126-135.
33. Sohn, S. J., J. Thompson, and A. Winoto. 2007. Apoptosis during negative selection of autoreactive thymocytes. Curr. Opin. Immunol. 19: 510-515.
34. Siggs, O. M., L. E. Makaroff, and A. Liston. 2006. The why and how of thymocyte negative selection. Curr. Opin. Immunol. 18: 175-183.
35. Martins, G., and K. Calame. 2008. Regulation and functions of Blimp-1 in T and B lymphocytes. Annu. Rev. Immunol. 26: 133-169.
36. Nutt, S. L., K. A. Fairfax, and A. Kallies. 2007. BLIMP1 guides the fate of effector B and T cells. Nat. Rev. Immunol. 7: 923-927.
37. Mandelbaum, J., G. Bhagat, H. Tang, T. Mo, M. Brahmachary, Q. Shen, A. Chadburn, K. Rajewsky, A. Tarakhovsky, L. Pasqualucci, and R. Dalla-Favera. 2010. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell 18: 568-579.
38. Calado, D. P., B. Zhang, L. Srinivasan, Y. Sasaki, J. Seagal, C. Unitt, S. Rodig, J. Kutok, A. Tarakhovsky, M. Schmidt-Supprian, and K. Rajewsky. 2010. Constitutive canonical NF-kB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. Cancer Cell 18: 580-589.
39. Diehl, S. A., H. Schmidlin, M. Nagasawa, S. D. van Haren, M. J. Kwakkenbos, E. Yasuda, T. Beaumont, F. A. Scheeren, and H. Spits. 2008. STAT3-mediated up-regulation of BLIMP1 Is coordinated with BCL6 down-regulation to control human plasma cell differentiation. J. Immunol. 180: 4805-4815.
40. Uckun, F. M., S. Qazi, H. Ma, L. Tuel-Ahlgren, and Z. Ozer. 2010. STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress. Proc. Natl. Acad. Sci. USA 107: 2902-2907.
41. Kwon, H., D. Thierry-Mieg, J. Thierry-Mieg, H. P. Kim, J. Oh, C. Tunyaplin, S. Carotta, C. E. Donovan, M. L. Goldman, P. Tailor, et al. 2009. Analysis of interleukin-21-induced Prdm1 gene regulation reveals functional cooperation of STAT3 and IRF4 transcription factors. Immunity 31: 941-952.
42. Crotty, S., R. J. Johnston, and S. P. Schoenberger. 2010. Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation. Nat. Immunol. 11: 114-120.
43. Moran, A. E., and K. A. Hogquist. 2012. T-cell receptor affinity in thymic development. Immunology 135: 261-267.
44. Martins, G. A., L. Cimmino, M. Shapiro-Shelef, M. Szabolcs, A. Herron, E. Magnusdottir, and K. Calame. 2006. Transcriptional repressor Blimp-1 regulates T cell homeostasis and function. Nat. Immunol. 7: 457-465.
45. Kallies, A., E. D. Hawkins, G. T. Belz, D. Metcalf, M. Hommel, L. M. Corcoran, P. D. Hodgkin, and S. L. Nutt. 2006. Transcriptional repressor Blimp-1 is essential for T cell homeostasis and self-tolerance. Nat. Immunol. 7: 466-474.
46. Garcia, J. F., G. Roncador, J. F. García, A. I. Sánz, L. Maestre, E. Lucas, S. Montes-Moreno, R. Fernandez Victoria, J. L. Martinez-Torrecuadrara, T. Marafioti, et al. 2006. PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma. Haematologica 91: 467-474.
47. Zhao, W. L., Y. Y. Liu, Q. L. Zhang, L. Wang, C. Leboeuf, Y. W. Zhang, J. Ma, J. F. Garcia, Y. P. Song, J. M. Li, et al. 2008. PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor. Blood 111: 3867-3871.
48. Gyory, I., G. Fejér, N. Ghosh, E. Seto, and K. L. Wright. 2003. Identification of a functionally impaired positive regulatory domain I binding factor 1 transcription repressor in myeloma cell lines. J. Immunol. 170: 3125-3133.
49. Reljic, R., S. D. Wagner, L. J. Peakman, and D. T. Fearon. 2000. Suppression of signal transducer and activator of transcription 3-dependent B lymphocyte terminal differentiation by BCL-6. J. Exp. Med. 192: 1841-1848.
50. Corse, E., R. A. Gottschalk, and J. P. Allison. 2011. Strength of TCR-peptide/MHC interactions and in vivo T cell responses. J. Immunol. 186: 5039-5045.
51. Bachmann, M. F., K. McKall-Faienza, R. Schmits, D. Bouchard, J. Beach, D. E. Speiser, T. W. Mak, and P. S. Ohashi. 1997. Distinct roles for LFA-1 and CD28 during activation of naive T cells: adhesion versus costimulation. Immunity 7: 549-557.
52. Viola, A., and A. Lanzavecchia. 1996. T cell activation determined by T cell receptor number and tunable thresholds. Science 273: 104-106.
53. Rudd, C. E., and H. Schneider. 2003. Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat. Rev. Immunol. 3: 544-556.
54. Labrecque, N., L. S. Whitfield, R. Obst, C. Waltzinger, C. Benoist, and D. Mathis. 2001. How much TCR does a T cell need? Immunity 15: 71-82.
55. Suzuki, A., M. T. Yamaguchi, T. Ohteki, T. Sasaki, T. Kaisho, Y. Kimura, R. Yoshida, A. Wakeham, T. Higuchi, M. Fukumoto, et al. 2001. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 14: 523-534.